NCT06702098View on ClinicalTrials.gov

Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 25, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

November 24, 2026

Conditions
Acute Myeloid Leukemia (AML)
Interventions
DRUG

iNK cells

Induced pluripotent stem cells derived NK cells.

Trial Locations (1)

523786

Guangzhou Ruixin Biotechnology Co., Ltd, Guangzhou

All Listed Sponsors
collaborator

Fifth Affiliated Hospital of Guangzhou Medical University

OTHER

lead

Guangzhou Ruixin Biotechnological Co., LTD

INDUSTRY

NCT06702098 - Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia | Biotech Hunter | Biotech Hunter